Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

Joel E. Gallant; Ellen Koenig; Jaime F. Andrade-Villanueva; Ploenchan Chetchotisakd; Edwin DeJesus; Francisco Antunes; Keikawus Arastéh; Giuliano Rizzardini; Jan Fehr; Hui C. Liu; Michael E. Abram; Huyen Cao; Javier Szwarcberg

doi:10.1097/QAI.0000000000000598

Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

Joel E. Gallant, Ellen Koenig, Jaime F. Andrade-Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C. Liu, Michael E. Abram, Huyen Cao, Javier Szwarcberg

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

Original language	English (US)
Pages (from-to)	338-340
Number of pages	3
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	69
Issue number	3
DOIs	https://doi.org/10.1097/QAI.0000000000000598
State	Published - Jul 1 2015
Externally published	Yes

Keywords

Antiretroviral
clinical trial
Cobicistat
HIV
pharmacoenhancer

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)
General Medicine

Access to Document

10.1097/QAI.0000000000000598

Cite this

Gallant, J. E., Koenig, E., Andrade-Villanueva, J. F., Chetchotisakd, P., DeJesus, E., Antunes, F., Arastéh, K., Rizzardini, G., Fehr, J., Liu, H. C., Abram, M. E., Cao, H., & Szwarcberg, J. (2015). Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. Journal of Acquired Immune Deficiency Syndromes, 69(3), 338-340. https://doi.org/10.1097/QAI.0000000000000598

Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. / Gallant, Joel E.; Koenig, Ellen; Andrade-Villanueva, Jaime F. et al.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 69, No. 3, 01.07.2015, p. 338-340.

Research output: Contribution to journal › Article › peer-review

Gallant, JE, Koenig, E, Andrade-Villanueva, JF, Chetchotisakd, P, DeJesus, E, Antunes, F, Arastéh, K, Rizzardini, G, Fehr, J, Liu, HC, Abram, ME, Cao, H & Szwarcberg, J 2015, 'Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results', Journal of Acquired Immune Deficiency Syndromes, vol. 69, no. 3, pp. 338-340. https://doi.org/10.1097/QAI.0000000000000598

@article{615ee6c4093d4314bdd5671ab43387ec,

title = "Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results",

abstract = "Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.",

keywords = "Antiretroviral, clinical trial, Cobicistat, HIV, pharmacoenhancer",

author = "Gallant, {Joel E.} and Ellen Koenig and Andrade-Villanueva, {Jaime F.} and Ploenchan Chetchotisakd and Edwin DeJesus and Francisco Antunes and Keikawus Arast{\'e}h and Giuliano Rizzardini and Jan Fehr and Liu, {Hui C.} and Abram, {Michael E.} and Huyen Cao and Javier Szwarcberg",

year = "2015",

month = jul,

day = "1",

doi = "10.1097/QAI.0000000000000598",

language = "English (US)",

volume = "69",

pages = "338--340",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate

T2 - Week 144 Results

AU - Gallant, Joel E.

AU - Koenig, Ellen

AU - Andrade-Villanueva, Jaime F.

AU - Chetchotisakd, Ploenchan

AU - DeJesus, Edwin

AU - Antunes, Francisco

AU - Arastéh, Keikawus

AU - Rizzardini, Giuliano

AU - Fehr, Jan

AU - Liu, Hui C.

AU - Abram, Michael E.

AU - Cao, Huyen

AU - Szwarcberg, Javier

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

AB - Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

KW - Antiretroviral

KW - clinical trial

KW - Cobicistat

KW - HIV

KW - pharmacoenhancer

UR - http://www.scopus.com/inward/record.url?scp=84933051378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933051378&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000598

DO - 10.1097/QAI.0000000000000598

M3 - Article

C2 - 26181707

AN - SCOPUS:84933051378

SN - 1525-4135

VL - 69

SP - 338

EP - 340

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 3

ER -

Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this